Results 131 to 140 of about 10,932 (172)
Metaparameter optimized hybrid deep learning model for next generation cybersecurity in software defined networking environment. [PDF]
Sci RepKumar CL +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hadashot Arkheologiyot - Excavations and Surveys in Israel, 2010
During July 2009, a sample salvage excavation was conducted in the Newe Rabin quarter of Or Yehuda (Permit No. A-5710; map ref. 187959-8000/658949-9035), after ancient remains were discovered during preliminary inspections. The excavation, undertaken on behalf of the Israel
Diego Barkan, Eriola Jakoel
+4 more sources
During July 2009, a sample salvage excavation was conducted in the Newe Rabin quarter of Or Yehuda (Permit No. A-5710; map ref. 187959-8000/658949-9035), after ancient remains were discovered during preliminary inspections. The excavation, undertaken on behalf of the Israel
Diego Barkan, Eriola Jakoel
+4 more sources
Proceedings of the third workshop on Hot topics in software defined networking, 2014
We present our experiences to date building ONOS (Open Network Operating System), an experimental distributed SDN control platform motivated by the performance, scalability, and availability requirements of large operator networks. We describe and evaluate two ONOS prototypes.
Pankaj Berde +10 more
openaire +1 more source
We present our experiences to date building ONOS (Open Network Operating System), an experimental distributed SDN control platform motivated by the performance, scalability, and availability requirements of large operator networks. We describe and evaluate two ONOS prototypes.
Pankaj Berde +10 more
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2003
ONO-6818 (CP-955) is the lead compound in a series of orally bioavailable neutrophil elastase inhibitors licensed from Cortech and under investigation by Ono for the potential treatment of inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and chronic obstructive pulmonary disease (COPD) [174095].
openaire +2 more sources
ONO-6818 (CP-955) is the lead compound in a series of orally bioavailable neutrophil elastase inhibitors licensed from Cortech and under investigation by Ono for the potential treatment of inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and chronic obstructive pulmonary disease (COPD) [174095].
openaire +2 more sources
Hadashot Arkheologiyot - Excavations and Surveys in Israel, 2011
During March-April 2005, a trial excavation was conducted at the Ono site in Or Yehuda (Permit No. A-4419; map ref. 18772-5/65924-7; HA-ESI 122), after a heap of potsherds was discovered while widening a street.
openaire +1 more source
During March-April 2005, a trial excavation was conducted at the Ono site in Or Yehuda (Permit No. A-4419; map ref. 18772-5/65924-7; HA-ESI 122), after a heap of potsherds was discovered while widening a street.
openaire +1 more source
Hadashot Arkheologiyot - Excavations and Surveys in Israel, 2004
A salvage excavation was conducted in March 2000 at the Ono site in Or Yehuda (A-3222*; Kafr 'Ana; map ref. NIG 18737-48/65914-24; OIG 13737-48/15914-24; HA-ESI 114), after antiquities were discovered during construction work. The excavation, on behalf of the Antiquities Authority,
openaire +1 more source
A salvage excavation was conducted in March 2000 at the Ono site in Or Yehuda (A-3222*; Kafr 'Ana; map ref. NIG 18737-48/65914-24; OIG 13737-48/15914-24; HA-ESI 114), after antiquities were discovered during construction work. The excavation, on behalf of the Antiquities Authority,
openaire +1 more source
IDrugs : the investigational drugs journal, 2003
Ono Pharmaceuticals is developing ONO-1714, a selective inducible NO synthase modulator, for the potential treatment of sepsis and hypotension. By March 1999, ONO-1714 had entered phase I trials [354023]. By June 2002, a phase II trial in hypotension during dialysis was ongoing in Japan and clinical pharmacology trials were underway in the UK [446138].
openaire +1 more source
Ono Pharmaceuticals is developing ONO-1714, a selective inducible NO synthase modulator, for the potential treatment of sepsis and hypotension. By March 1999, ONO-1714 had entered phase I trials [354023]. By June 2002, a phase II trial in hypotension during dialysis was ongoing in Japan and clinical pharmacology trials were underway in the UK [446138].
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2004
ONO-2506 is an enantiomeric, three carbon atom homolog of valproic acid under development by ONO Pharmaceutical for the potential treatment of stroke, as well as Alzheimer's and Parkinson's disease. The injectable formulation (Proglia) is undergoing phase II trials in the US and Japan for acute-phase cerebral infarction, and the oral formulation ...
openaire +1 more source
ONO-2506 is an enantiomeric, three carbon atom homolog of valproic acid under development by ONO Pharmaceutical for the potential treatment of stroke, as well as Alzheimer's and Parkinson's disease. The injectable formulation (Proglia) is undergoing phase II trials in the US and Japan for acute-phase cerebral infarction, and the oral formulation ...
openaire +1 more source
ONO-5046 (Ono Pharmaceutical).
IDrugs : the investigational drugs journal, 2005ONO-5046 (sivelestat) is a competitive inhibitor of human neutrophil elastase from Ono Pharmaceutical, which is awaiting FDA approval for the treatment of pulmonary fibrosis and idiopathic interstitial pneumonia [349488]. An NDA was filed in Japan in September 1998 [299667].
openaire +1 more source